FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2132238257> ?p ?o ?g. }

• W2132238257 endingPage "35" @default.
• W2132238257 startingPage "29" @default.
• W2132238257 abstract "Abstract Previous studies have suggested that the level of residual disease at the end of therapy predicts outcome in chronic lymphocytic leukemia (CLL). However, available methods for detecting CLL cells are either insensitive or not routinely applicable. A flow cytometric assay was developed that can differentiate CLL cells from normal B cells on the basis of their CD19/CD5/CD20/CD79b expression. The assay is rapid and can detect one CLL cell in 104 to 105leukocytes in all patients. We have compared this assay to conventional assessment in 104 patients treated with CAMPATH-1H and/or autologous transplant. During CAMPATH-1H therapy, circulating CLL cells were rapidly depleted in responding patients, but remained detectable in nonresponders. Patients with more than 0.01 × 109/L circulating CLL cells always had significant (&gt; 5%) marrow disease, and blood monitoring could be used to time marrow assessments. In 25 out of 104 patients achieving complete remission by National Cancer Institute (NCI) criteria, the detection of residual bone marrow disease at more than 0.05% of leukocytes in 6 out of 25 patients predicted significantly poorer event-free (P = .0001) and overall survival (P = .007). CLL cells are detectable at a median of 15.8 months (range, 5.5-41.8) posttreatment in 9 out of 18 evaluable patients with less than 0.05% CLL cells at end of treatment. All patients with detectable disease have progressively increasing disease levels on follow-up. The use of sensitive techniques, such as the flow assay described here, allow accurate quantitation of disease levels and provide an accurate method for guiding therapy and predicting outcome. These results suggest that the eradication of detectable disease may lead to improved survival and should be tested in future studies." @default.
• W2132238257 created "2016-06-24" @default.
• W2132238257 creator A5004618702 @default.
• W2132238257 creator A5008546299 @default.
• W2132238257 creator A5016246851 @default.
• W2132238257 creator A5030791454 @default.
• W2132238257 creator A5031215764 @default.
• W2132238257 creator A5034560778 @default.
• W2132238257 creator A5035489508 @default.
• W2132238257 creator A5039072697 @default.
• W2132238257 creator A5047631289 @default.
• W2132238257 creator A5067838760 @default.
• W2132238257 creator A5089096852 @default.
• W2132238257 date "2001-07-01" @default.
• W2132238257 modified "2023-10-02" @default.
• W2132238257 title "Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy" @default.
• W2132238257 cites W1243376384 @default.
• W2132238257 cites W1480851099 @default.
• W2132238257 cites W1833241997 @default.
• W2132238257 cites W1968271697 @default.
• W2132238257 cites W1968444583 @default.
• W2132238257 cites W1973190434 @default.
• W2132238257 cites W1981590433 @default.
• W2132238257 cites W1998582864 @default.
• W2132238257 cites W2004323633 @default.
• W2132238257 cites W2012190233 @default.
• W2132238257 cites W2014501259 @default.
• W2132238257 cites W2033257800 @default.
• W2132238257 cites W2037748503 @default.
• W2132238257 cites W2040016073 @default.
• W2132238257 cites W2046110140 @default.
• W2132238257 cites W2052415602 @default.
• W2132238257 cites W2054493028 @default.
• W2132238257 cites W2055037217 @default.
• W2132238257 cites W2061365129 @default.
• W2132238257 cites W2072441151 @default.
• W2132238257 cites W2072899219 @default.
• W2132238257 cites W2081143563 @default.
• W2132238257 cites W2119768912 @default.
• W2132238257 cites W2228874111 @default.
• W2132238257 cites W2244873192 @default.
• W2132238257 cites W2294516256 @default.
• W2132238257 cites W4253879795 @default.
• W2132238257 cites W60865865 @default.
• W2132238257 cites W74992319 @default.
• W2132238257 doi "https://doi.org/10.1182/blood.v98.1.29" @default.
• W2132238257 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11418459" @default.
• W2132238257 hasPublicationYear "2001" @default.
• W2132238257 type Work @default.
• W2132238257 sameAs 2132238257 @default.
• W2132238257 citedByCount "252" @default.
• W2132238257 countsByYear W21322382572012 @default.
• W2132238257 countsByYear W21322382572013 @default.
• W2132238257 countsByYear W21322382572014 @default.
• W2132238257 countsByYear W21322382572015 @default.
• W2132238257 countsByYear W21322382572016 @default.
• W2132238257 countsByYear W21322382572017 @default.
• W2132238257 countsByYear W21322382572018 @default.
• W2132238257 countsByYear W21322382572019 @default.
• W2132238257 countsByYear W21322382572020 @default.
• W2132238257 countsByYear W21322382572021 @default.
• W2132238257 countsByYear W21322382572022 @default.
• W2132238257 countsByYear W21322382572023 @default.
• W2132238257 crossrefType "journal-article" @default.
• W2132238257 hasAuthorship W2132238257A5004618702 @default.
• W2132238257 hasAuthorship W2132238257A5008546299 @default.
• W2132238257 hasAuthorship W2132238257A5016246851 @default.
• W2132238257 hasAuthorship W2132238257A5030791454 @default.
• W2132238257 hasAuthorship W2132238257A5031215764 @default.
• W2132238257 hasAuthorship W2132238257A5034560778 @default.
• W2132238257 hasAuthorship W2132238257A5035489508 @default.
• W2132238257 hasAuthorship W2132238257A5039072697 @default.
• W2132238257 hasAuthorship W2132238257A5047631289 @default.
• W2132238257 hasAuthorship W2132238257A5067838760 @default.
• W2132238257 hasAuthorship W2132238257A5089096852 @default.
• W2132238257 hasBestOaLocation W21322382571 @default.
• W2132238257 hasConcept C113067387 @default.
• W2132238257 hasConcept C126322002 @default.
• W2132238257 hasConcept C143998085 @default.
• W2132238257 hasConcept C18031839 @default.
• W2132238257 hasConcept C203014093 @default.
• W2132238257 hasConcept C2776863199 @default.
• W2132238257 hasConcept C2777938653 @default.
• W2132238257 hasConcept C2778461978 @default.
• W2132238257 hasConcept C2778822529 @default.
• W2132238257 hasConcept C2778957590 @default.
• W2132238257 hasConcept C2779134260 @default.
• W2132238257 hasConcept C2779338263 @default.
• W2132238257 hasConcept C2779823535 @default.
• W2132238257 hasConcept C2780007613 @default.
• W2132238257 hasConcept C2781071720 @default.
• W2132238257 hasConcept C553184892 @default.
• W2132238257 hasConcept C71924100 @default.
• W2132238257 hasConcept C90924648 @default.
• W2132238257 hasConceptScore W2132238257C113067387 @default.
• W2132238257 hasConceptScore W2132238257C126322002 @default.
• W2132238257 hasConceptScore W2132238257C143998085 @default.
• W2132238257 hasConceptScore W2132238257C18031839 @default.

• next